HAMBURG, GERMANY, AND TORONTO, ON / ACCESSWIRE / April 2, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc.
About Fate Therapeutics’ iPSC Product PlatformThe Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell ...
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today ...
ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...
CLEVELAND and SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Cell X Technologies, pioneers in automated cell processing solutions, and Aspen Neuroscience, Inc., dedicated to autologous regenerative medicine, ...
SEATTLE--(BUSINESS WIRE)--Curi Bio, a leading developer of human iPSC-based platforms for drug discovery, today announced the ComboMat™ platform, a proprietary human iPSC-derived cardiomyocyte ...
Pulse™ Cell Line platform provides therapeutic developers iPSC cell lines and iPSC-based cell lines ready for their unique edits to create product specific working and master cell banks Echo™ Cell ...
ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback